BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines collaboration Right-to-Access IP Revenue ($M, FY19–FY22) ($M)
Form 10-Q / 10-K Collaboration Note
Latest, Q3 2023
52
Period ended Sep 30, 2023
Change on a year earlier
+98.5%
26.2 in Q3 2022
History
11 quarters
Since Q1 2021
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration Right-to-Access IP Revenue ($M, FY19–FY22) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2023 | Sep 30, 2023 | 52 | +98.5% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 26.2 | 0.0% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 26.2 | 0.0% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 26.2 | +555.0% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 26.2 | – | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 26.2 | – | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 26.2 | – | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 4 | – | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 0 | – | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 0 | – | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 0 | – | Form 10-Q (filed 2022-05-09) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Collaboration Right-to-Access IP Revenue ($M, FY19–FY22) ($M), quarterly Q1 2021–Q3 2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rev_collab_ip_access
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.